26/06/2026
Thank you to everyone who attended our events in Trinity College, where we focused on patient-centered clinical updates, followed by the European Federation of Associations of Patients with Haemochromatosis (EFAPH) AGM.
These events brought together member association representatives, patients, researchers, academics and medical experts, some of who were attending the overall European Iron Club Conference, hosted by Professor John and Ryan and Professor Suzanne Cloonan.
The first event was officially opened by Prof. Mayka Sanchez. Prof. Domenico Girelli delivered a comprehensive presentation regarding recent advances in iron dysregulation. He explored the biological importance of iron, its historical context, and the dual clinical risks associated with iron imbalance. He detailed the critical biological roles played by hepcidin and ferroportin, and introduced emerging pharmaceutical developments, including Rusfertide (a hepcidin mimetic currently in Phase 3) and Vamifeport (a ferroportin inhibitor currently in Phase 2).
Following this presentation, Sebastian Kaluscha, a Senior Clinical Scientist from CSL Behring, provided an operational update on the "Ferroclear" clinical trial. A small cohort of HH patients are completely intolerant to standard phlebotomy or fail to respond efficiently, highlighting an urgent necessity for new pharmacological treatments. The ongoing trial is presently in its Phase 2 "proof of concept" stage to rigorously evaluate the molecule's safety and efficacy.
The business of the EFAPH AGM coverd administrative updates, including website and newsfeed alignment by Howard Don (HI) and Julie McHenry (EFAPH). Prof. Sanchez delivered a summary of the European Iron Club (EIC) conference, and Dr. Barbara Butzeck presented the EFAPH activity report. Individual country updates were shared by Germany, Ireland, Portugal, Spain, Italy, the Netherlands, France, and Hungary.
If you would like any further information on these events or a copy of the abstracts from the EIC Conference, please email Miriam, [email protected]